{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:47:33Z","timestamp":1793767653293,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy Committee","award":["CPA-Z05-ZC-2021-003"],"award-info":[{"award-number":["CPA-Z05-ZC-2021-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00228-024-03691-9","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:50:56Z","timestamp":1714575056000},"page":"1219-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics of nirmatrelvir\/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients"],"prefix":"10.1007","volume":"80","author":[{"given":"Xueyin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"issue":"2","key":"3691_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","volume":"45","author":"F Lemaitre","year":"2023","unstructured":"Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O et al (2023) Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19. Ther Drug Monit 45(2):191\u2013199","journal-title":"Ther Drug Monit"},{"issue":"2","key":"3691_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41401-018-0070-2","volume":"40","author":"R Fu","year":"2019","unstructured":"Fu R, Tajima S, Suetsugu K, Watanabe H, Egashira N, Masuda S (2019) Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. Acta Pharmacol Sin 40(2):151\u2013159","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"3691_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261\u2013307","journal-title":"Ther Drug Monit"},{"issue":"8","key":"3691_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40261-022-01180-4","volume":"42","author":"N Berar Yanay","year":"2022","unstructured":"Berar Yanay N, Bogner I, Saker K, Tannous E (2022) Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19. Clin Drug Investig 42(8):693\u2013695","journal-title":"Clin Drug Investig"},{"issue":"8","key":"3691_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1097\/00007890-199910270-00026","volume":"68","author":"PJ Gregoor","year":"1999","unstructured":"Gregoor PJ, van Gelder T, van der Ende ME, Ijzermans JN, Weimar W (1999) Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation 68(8):1210","journal-title":"Transplantation"},{"issue":"5","key":"3691_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 90(5):666\u2013673","journal-title":"Clin Pharmacol Ther"},{"key":"3691_CR7","doi-asserted-by":"publisher","first-page":"1150341","DOI":"10.3389\/fimmu.2023.1150341","volume":"14","author":"Y Tang","year":"2023","unstructured":"Tang Y, Li Y, Song T (2023) Optimizing the use of nirmatrelvir\/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies. Front Immunol 14:1150341","journal-title":"Front Immunol"},{"issue":"5","key":"3691_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","volume":"77","author":"F Lemaitre","year":"2022","unstructured":"Lemaitre F, Gr\u00e9goire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E (2022) Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie 77(5):509\u2013521","journal-title":"Therapie"},{"issue":"11","key":"3691_CR9","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","volume":"7","author":"A Devresse","year":"2022","unstructured":"Devresse A, Briol S, De Greef J, Lemaitre F, Boland L, Haufroid V et al (2022) Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2. Kidney Int Rep 7(11):2356\u201363","journal-title":"Kidney Int Rep"},{"issue":"7","key":"3691_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/ajt.16955","volume":"22","author":"NW Lange","year":"2022","unstructured":"Lange NW, Salerno DM, Jennings DL, Choe J, Hedvat J, Kovac DB et al (2022) Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant 22(7):1925\u20131926","journal-title":"Am J Transplant"},{"issue":"8","key":"3691_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/ajt.16997","volume":"22","author":"AX Wang","year":"2022","unstructured":"Wang AX, Koff A, Hao D, Tuznik NM, Huang Y (2022) Effect of nirmatrelvir\/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant 22(8):2117\u20132119","journal-title":"Am J Transplant"},{"issue":"1","key":"3691_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cpt.2603","volume":"112","author":"RSP Singh","year":"2022","unstructured":"Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R et al (2022) Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther 112(1):101\u2013111","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3691_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cpt.2688","volume":"112","author":"SS Toussi","year":"2022","unstructured":"Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O et al (2022) Pharmacokinetics of oral nirmatrelvir\/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment. Clin Pharmacol Ther 112(4):892\u2013900","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3691_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106997","volume":"63","author":"R Dong","year":"2023","unstructured":"Dong R, Huang Y, Ling X, Li L, Yu W, Jiang S (2023) High concentrations of nirmatrelvir\/ritonavir in critically ill patients receiving continuous renal replacement therapy. Int J Antimicrob Agents 63(1):106997","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"3691_CR15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.05270522","volume":"17","author":"S Hiremath","year":"2022","unstructured":"Hiremath S, McGuinty M, Argyropoulos C, Brimble KS, Brown PA, Chagla Z et al (2022) Prescribing nirmatrelvir\/ritonavir for COVID-19 in advanced CKD. Clin J Am Soc Nephrol 17(8):1247\u20131250","journal-title":"Clin J Am Soc Nephrol"},{"key":"3691_CR16","doi-asserted-by":"publisher","first-page":"1053814","DOI":"10.3389\/fphar.2023.1053814","volume":"14","author":"A Kale","year":"2023","unstructured":"Kale A, Shelke V, Dagar N, Anders HJ, Gaikwad AB (2023) How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front Pharmacol 14:1053814","journal-title":"Front Pharmacol"},{"issue":"4","key":"3691_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35(4):275\u201391","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3691_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1128\/AAC.41.5.898","volume":"41","author":"A Hsu","year":"1997","unstructured":"Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A et al (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41(5):898\u2013905","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3691_CR19","first-page":"552","volume":"26","author":"T Koudriakova","year":"1998","unstructured":"Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E et al (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4\/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26(6):552\u2013561","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3691_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/FTD.0b013e318225384f","volume":"33","author":"NY Rakhmanina","year":"2011","unstructured":"Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ et al (2011) CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir\/ritonavir in HIV-infected children. Ther Drug Monit 33(4):417\u2013424","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03691-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03691-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:05:52Z","timestamp":1720163152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03691-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3691"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03691-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University (approved no. 2023218), and was carried out in accordance with the legal requirements, institutional guidelines, and the Declaration of Helsinki. Donor kidneys from executed prisoners were not utilized for the patients in this study. Informed consent to participate in the study was obtained from all patients themselves or their legal representatives and the privacy rights always be observed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}